gene_symbol
HLA-DPB1
hgnc_id
HGNC:4940
binding_type
antigen recognition
cytotoxicity
YES
cytotoxicity_type
DIRECT
cytotoxicity_mechanism
TILs use native TCRs (CD4+ T cells) to recognize tumor-derived peptides presented on HLA-DP (MHC II) and directly lyse target cells via perforin/granzyme and Fas–FasL pathways, with cytokines (IFN-γ/TNFα) augmenting cytotoxicity.
enzyme_product
Off
epitope
On
variant
On
isoform
Off
hla_specific
On
gated
Off
other_modifier
Patient-specific peptide–MHC complex; CD4+ TCR restriction
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06532799
disease_id_num_tar_ref
1330
drug_id_num_tar_ref
3603